Rejuvenate old stem cells
Kizoo invests in Seed Financing for Rejuvenation Startup Mogling Bio
Mogling Bio, a privately held biotech company, announces that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level.
Symbolic image
Computer generated picture
Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by increased activity of the protein CDC42. This loss of structure leads to decreased production and quality of blood and immune cells. It can cause leukemia, various blood diseases, and severely weaken the immune system. Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells. Treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.
The underlying technology was developed over the last 15 years by the two scientific co-founders, Prof. Yi Zheng, co-director of the Cincinnati Children’s Hospital Cancer and Blood Diseases Institute and leader of the Signaling and Drug Discovery Program at the Cincinnati Children’s Research Foundation, and Prof. Dr. Hartmut Geiger, director of the Institute of Molecular Medicine at Ulm University in Germany.
“We are really excited that Kizoo's financial support will allow us to pursue our goal of rejuvenating aging stem cells, which are so important for blood cell production and the immune system. Our approach has particular potential in treating diseases of the blood system and improving the immune system”, said Dr. Jürgen Reess, CEO of Mogling Bio. Dr. Reess previously held the position of Senior Vice President at Boehringer Ingelheim Pharma, where he supervised the development, approval, and launch of numerous blockbuster therapies for autoimmune diseases, interstitial lung diseases, central nervous system disorders, and cancer.
“We believe that Mogling Bio's technology is groundbreaking by truly rejuvenating old stem cells - not only alleviating age-related diseases, but reversing age-related decline in immune system function”, added Frank Schueler, Managing Director of Kizoo Technology Capital.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
